Open | - |
Close | - |
Volume / Avg. | 0 / 417.932K |
Day Range | - - - |
52 Wk Range | 14.620 - 43.810 |
Market Cap | $891.702M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 38 |
Short Interest | 22.37% |
Days to Cover | 10.88 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Arcturus Therapeutics (NASDAQ: ARCT) through any online brokerage.
Other companies in Arcturus Therapeutics’s space includes: Macrogenics (NASDAQ:MGNX), Cabaletta Bio (NASDAQ:CABA), ARS Pharmaceuticals (NASDAQ:SPRY), Zentalis Pharma (NASDAQ:ZNTL) and Centessa Pharmaceuticals (NASDAQ:CNTA).
The latest price target for Arcturus Therapeutics (NASDAQ: ARCT) was reported by Canaccord Genuity on Monday, March 11, 2024. The analyst firm set a price target for 87.00 expecting ARCT to rise to within 12 months (a possible 162.60% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Arcturus Therapeutics (NASDAQ: ARCT) is $33.13 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Arcturus Therapeutics.
Arcturus Therapeutics’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Arcturus Therapeutics.
Arcturus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.